From May 3rd to 6th, DPM Company showcased at the 105th AATS Annual Meeting held in Seattle, USA. As one of the most influential academic conferences in the global cardiothoracic surgery field, the meeting gathered top surgical experts, scholars, and medical enterprise representatives from over 50 countries worldwide. It focused on the latest technological advancements and clinical practice innovations in cardiothoracic diseases, providing an excellent platform for global academic and industry peers.
DPM highlighted its flagship products—the 3D 4K Fluorescence Endoscopic Imaging System and the 4K Fluorescence Endoscopic Imaging System. Based on our profound foundation and cutting-edge innovation in molecular imaging technology, we offered revolutionary solutions targeting clinical pain points in thoracic surgery, such as providing effective and precise localization of pulmonary nodules, esophageal cancer lymph node dissection navigation, and intraoperative vascular/neural protection.
During the exhibition, the DPM booth was packed with visitors. Lots of medical professionals from around the world showed keen interest in our products, actively inquiring about technical details and application scenarios. Some thoracic surgery experts engaged in in-depth exchanges with the DPM team regarding the clinical value of fluorescence molecular imaging technology in real-time intraoperative navigation. After experiencing our system on-site, they remarked that DPM's fluorescence imaging clarity surpasses similar products, capable of bringing powerful imaging assistance during surgery.
Participating in this grand event holds multidimensional significance for our company. It not only enhanced DPM's international recognition and influence, but also established valuable cooperation opportunities, taking a crucial step on our path to overseas market. Through AATS 2025, we learned about the latest research and technological trends in the international thoracic surgery field and conducted in-depth exchanges with top global surgical experts. This will help DPM maintain a leading position in product development and technological innovation to better meet clinical needs.
As a "Leader in the Post-precision Medicine Era," DPM will continue to promote innovation in precision surgical technology, expand our product lines, deepen technological applications, and contribute greater strength to medical technology advancement and patient health improvement. We look forward to exploring the future of molecular imaging intraoperative navigation with more global medical professionals in the future.
